SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 1.510-3.8%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote ()11/23/1996 4:32:00 PM
From: Don W Stone   of 82
 
Ten (10) THINGS ARE CERTAIN ABOUT NVX:

1) NVX will get FDA approval for their DTaP vaccine and their "Label" will read the best in the market place.
2) Abbott Labs is as qualified as anyone to get that word out.
3) NVX will be first to market with a real combinant DTaP-IPV vaccine.
4) NVX will be the first to market witht the Strep B vaccine.
5) NVX will be the first with an advanced combinant DTaP-IPV-Hib vaccine.
6) NVX holds patents and rights to some extremely attractive vaccine technologies
7) NVX is far and above the best candidate in the lucrative vaccine business to be taken over by a large drug company.
8) There is bound to be alot more good news coming.
9) There indeed will be a "short squeeze "
10) Institutions are buying on dips.
and there really are many more.

AND THAT IS WHY THE STOCK WAS STRONG THIS PAST WEEK IMHO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News